Treatment of subcutaneous and orthotopic tumor xenografts consisted of injection of IgG1-control and ADAM17-inhibitory antibody injection (5 mg MEDI3622/kg bodyweight, i.p.), respectively, on two consecutive days, followed by (sham-)irradiation on day 3 and additional treatment with IgG1 control and MEDI3622 (5 mg/kg bodyweight, i.p.)on two consecutive days (days 4 and 5). The gene discussed is ADAM17; the disease is neoplasm.